Loading…
Loading…
The Schwab Fundamental U.S. Large Company ETF is upgraded to buy, reflecting a less favorable macroeconomic and AI outlook. FNDX reduces mega-cap bias by weighting holdings on fundamentals—revenue, operating cash flow, dividends, and net buybacks—rather than market capitalization. This approach results in a less concentrated portfolio, offering diversification benefits compared to traditional broad market index funds.
The arrival of June usually signals a seasonal slowdown for many people, but our ETF industry clearly missed the memo. Instead of heading to the beach or stopping to watch the World Cup, the ETF ecosystem had a wave of milestones, structural changing-of-the-guards, and high-profile index provider consolidation.
Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the Schwab Fundamental U.S. Large Company ETF (FNDX), a passively managed exchange traded fund launched on August 13, 2013.
Value investing spent most of the post-2010 cycle losing to growth, but the past year has flipped that script.
Making its debut on 08/13/2013, smart beta exchange traded fund Schwab Fundamental U.S. Large Company ETF (FNDX) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
Schwab Fundamental U.S. Large Company Index ETF offers a diversified, fundamentally weighted portfolio with strong value characteristics and steady dividend growth. FNDX maintains lower sector and company concentration risk than the Russell 1000, with no sector above 16% and the top issuer at 4.5%. FNDX has recently outperformed the Russell 1000 over 12 months, but since 2013, it has lagged the benchmark and trails close competitor IUS in recent returns.
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection solutions to reduce the spread of harmful pathogens, announces that it has entered into an agreement dated April 28, 2026, with Innovotech Labs Corporation ("Innovotech") (TSXV: IOT) (OTCQB: IOTCF) to support regulatory planning for its coated catheter program. Under the agreement, Innovotech will conduct regulatory research to determine the appropriate U.S. Food and Drug Administration ("FDA") classification and regulatory pathway for FendX's coated Foley catheter product currently in development.
Project aims to develop a scalable manufacturing process and represents a key next step toward the commercialization of the surface coating Vancouver, British Columbia--(Newsfile Corp. - April 15, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection solutions to reduce the spread of harmful pathogens, announces the signing of a statement of work ("SOW") dated April 14, 2026 with Galenvs Sciences Inc. ("Galenvs"), a Canadian contract manufacturing and service organization, to initiate pilot-scale manufacturing of FendX's liquid surface coating. Dr. Carolyn Myers, CEO of FendX states, "This pilot-scale project is an important step toward the commercialization of our new surface coating formulation, which has demonstrated promising antimicrobial activity and durability while offering a potentially streamlined pathway to commercial scale-up at a low cost of manufacturing.